Publications

2022

Marzio A, Kurz E, Sahni JM, Di Feo G, Puccini J, Jiang S, et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell. 2022;185(1):169-183.e19.
Brendel M, Getseva V, Assaad MA, Sigouros M, Sigaras A, Kane T, et al. Weakly-supervised tumor purity prediction from frozen H&E stained slides. EBioMedicine. 2022;80:104067.
Choi SY, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules. 2022;12(11).
Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, et al. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022;6:e2200329.
Hissong E, Mowers J, Zhao L, Greenson JK, Bachman M, Lamps LW. Histologic and Clinical Correlates of Multiplex Stool Polymerase Chain Reaction Assay Results. Arch Pathol Lab Med. 2022;146(12):1479-1485.
Sun J, Greenblatt MB. To the bones: mapping the skeletal LEPR+ pool to component cell types. EMBO J. 2022;41(4):e110343.
Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordoñez A, Reina-Campos M, et al. The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022;39(6):110792.
Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2022;28(1):212.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700